Fennec Pharmaceuticals Delivers Robust Performance in Q2 2025

Fennec Pharmaceuticals Posts Strong Second Quarter 2025 Results

~ Achieved Total Net Revenues of $9.7 Million in Q2 2025 ~

~ Experienced Double-Digit Growth in New Accounts and Strong Demand for PEDMARK ~

~ Launching PEDMARQSI in Additional EU Countries ~

~ Anticipated Results from Japan's Clinical Trials in Late 2025 ~

RESEARCH TRIANGLE PARK, N.C. -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX:FRX), a specialized pharmaceutical company dedicated to improving patient outcomes, has reported its financial results for the second quarter of 2025, showcasing considerable growth and innovation.

“Our performance in Q2 reflects the successful implementation of our revamped strategy, with revenues soaring 33% compared to last year,” expressed Jeff Hackman, CEO of Fennec Pharmaceuticals. “We’re witnessing remarkable demand for PEDMARK® as it gains traction among both community practices and academic institutions. Our strategy, aimed at increasing awareness and enhancing patient support, is clearly paying off.”

Business Highlights

Continued Expansion in Key Accounts

Fennec’s innovative segmentation approach in targeting accounts has significantly elevated both new and existing customer engagement. Growth was particularly strong within large community practices and academic centers.

Inclusion in National Oncology Group Formulary

A prominent national oncology group has added PEDMARK® to its formulary for patients under 40, marking a pivotal step in broader acceptance and integration within the community oncology setting. This decision signifies a growing recognition of the importance of protecting younger patients from cisplatin-induced hearing loss.

Positive Quality Intervention Issued for PEDMARK

NCODA issued a Positive Quality Intervention (PQI) for PEDMARK®, offering vital clinical data and guidance for healthcare professionals managing pediatric patients at risk of ototoxicity.

Growth in Enrollment for Fennec HEARS™ Program

The patient support program has seen an increase in enrollment, showcasing our commitment to improving patient experiences through enhanced service offerings and streamlined nursing support.

Upcoming Events

NASDAQ Closing Bell Ceremony in September

Fennec’s leadership team will join patients and their families to ring the NASDAQ closing bell, a symbol of our commitment to community involvement and awareness.

Presentation at H.C. Wainwright Global Investment Conference

Management is scheduled to present insights and updates at this prestigious conference, further solidifying our position within the investment community.

Financial Overview for Q2 2025

In the second quarter, Fennec recorded net product sales of approximately $9.7 million, a notable increase from $7.3 million in the same period last year due to an intensified focus on pediatric populations.

Key Financial Details

• Selling and Marketing Expenses: $4.4 million, a slight decrease from $4.6 million last year, reflecting optimized spending on effective marketing strategies.
• General and Administrative Expenses: $7.0 million, consistent with previous year, primarily attributed to increased IP expenses.
• Cash Position: Ended the quarter with $18.7 million in cash, adjusted for projected operational expenses typical for the season.

Recent Developments for PEDMARK®

PEDMARK has emerged as a breakthrough in preventing cisplatin-induced hearing loss for pediatric patients. With over 500,000 cancer diagnoses annually within the U.S. involving platinum-based treatments, the need for preventive therapies like PEDMARK is critical.

PEDMARK® offers a unique formulation that is both FDA approved and respected by health authorities worldwide, indicating a robust future for patient care innovation. As clinical results continue to affirm its efficacy, Fennec Pharmaceuticals is set to strengthen its footprint in oncological care.

Frequently Asked Questions

What are the key financial results for Fennec Pharmaceuticals in Q2 2025?

The key result includes total net revenues of $9.7 million, representing a 33% increase from Q2 of 2024.

What progress has Fennec made in expanding PEDMARK?

Fennec has added new accounts in large community practices and increased acknowledgment of its impact in pediatric oncology.

What events are coming up for Fennec Pharmaceuticals?

Fennec will participate in the NASDAQ closing bell ceremony and present at the H.C. Wainwright Global Investment Conference.

Has PEDMARK received any endorsements?

Yes, PEDMARK is endorsed by prestigious oncology groups and has been recommended for use in the adolescent and young adult population.

What is the future outlook for Fennec Pharmaceuticals?

With ongoing growth and expansion strategies, coupled with strong demand for PEDMARK, the outlook is robust for Fennec Pharmaceuticals in the coming years.

About The Author

Hi there I'm 38-year-old author and financial consultant Owen Jenkins. Having worked in the financial sector for more than ten years, I am well-versed in the subtleties and complexity that mold our financial environment. Following a degree in finance, I worked in a number of financial institutions honing my abilities in market analysis, financial planning, and investment strategies.

My love is teaching others about investing and personal finance. My goal in writing many books and articles has been to demystify financial ideas and give readers the information they need to make wise financial decisions. I write with a direct, useful style that emphasizes doable suggestions for daily living.

Along with writing, I lead webinars and seminars where I impart knowledge on how to successfully negotiate the financial world. I also write for financial journals and show up as a guest expert on financial news programs a lot. Whether they are new to investing or want to improve their approach, my mission is to enable people to take charge of their financial futures.

Beyond work, I like to hike, play the guitar, and spend time with my family. I think that balance is crucial and want to encourage people to strike a balance between their financial aspirations and their hobbies. I want to help people succeed and achieve financial security through my work, so having a good influence.

Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.